Medicare billing address
CMS Medicare provider billing file
925 Trailwood DrYoungstown, OH 44512
CMS public data · NPI 1003806134
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Ghazaleh Bigdeli, M.D.
Specialty
Credential
M.D.
NPI
1003806134
Primary source state
OH
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Ghazaleh Bigdeli, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
925 Trailwood DrCMS Doctors & Clinicians file
925 Trailwood DrIn the 2024 CMS provider billing file, this NPI had 520 Medicare beneficiaries and 1,633 total services. The average beneficiary age was 75, and the average HCC risk score was 2.4.
Total Medicare allowed amount
$176,917.53
Total Medicare payment amount
$138,026.59
Medicare beneficiaries
520
Total services
1,633
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
75%
CMS beneficiary-panel share
COPD
56%
CMS beneficiary-panel share
Diabetes
49%
CMS beneficiary-panel share
Heart failure
46%
CMS beneficiary-panel share
Ischemic heart disease
44%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 344 | $112.41 |
| Critical care, first 30-74 minutes | 230 | $201.59 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 223 | $120.50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 129 | $74.68 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 100 | $164.26 |
| Test to examine how well the lungs exchange gases | 86 | $51.26 |
| Test to determine lung volumes using sensors | 84 | $50.89 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 83 | $35.57 |
| Red blood cell hemoglobin concentration | 66 | $6.86 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 41 | $85.47 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1003806134. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 312 | 386 | $240,993.79 |
| 2 | Albuterol Sulfate Hfa | Albuterol Sulfate | 265 | 314.5 | $7,090.39 |
| 3 | Montelukast Sodium | Montelukast Sodium | 214 | 385.3 | $2,110.35 |
| 4 | Breo Ellipta | Fluticasone/Vilanterol | 121 | 144 | $54,817.32 |
| 5 | Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 89 | 93 | $59,615.06 |
| 6 | Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 85 | 107 | $48,044.58 |
| 7 | Prednisone | Prednisone | 68 | 70 | $150.43 |
| 8 | Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 51 | 56 | $26,171.61 |
| 9 | Azithromycin | Azithromycin | 49 | 60.7 | $179.11 |
| 10 | Ventolin Hfa | Albuterol Sulfate | 39 | 47.8 | $3,053.31 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
1997
Group/practice field
Pulmonary Rehabilitation Associates
Telehealth reported
Not reported
Secondary specialty fields reported by CMS: Critical Care (Intensivists), Pulmonary Disease, Sleep Medicine.
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.